<DOC>
	<DOCNO>NCT00635505</DOCNO>
	<brief_summary>This 12-week clinical study evaluate safety efficacy Albuterol Sulfate HFA Inhalation Aerosol ( Albuterol-HFA , : A004 ) , Armstrong 's proposed HFA formulation meter dose inhaler ( MDI ) Albuterol ( Treatment T ) , comparison : 1 . Placebo control : ( HFA propellant , Treatment P ) ; 2 . Active control : 3M/Key 's Proventil-HFA ( Treatment R ) . The treatment give self-administered oral inhalation adult adolescent patient mild-to-moderate asthma , 12-weeks . Dosing regimen throughout 12-week study two actuation four time daily ( QID ) .</brief_summary>
	<brief_title>Controlled , 12-Week Study Albuterol HFA Versus Active Control , Proventil ( R ) -HFA Asthmatic Patients</brief_title>
	<detailed_description>This randomize , parallel , multicenter , 12-week study adolescent adult patient mild-to-moderate asthma , evaluate efficacy safety Armstrong 's Albuterol-HFA MDI , comparison Placebo Control Active Control Proventil-HFA . While Albuterol-HFA ( Treatment T ) Placebo ( Treatment P ) double-blinded subject investigational staff , active comparator drug , Proventil-HFA ( Treatment R ) , evaluator-blinded , due : ( 1 ) physical appearance differ T P device ; ( 2 ) unavailability Proventil-HFA placebo would otherwise use double-dummy design . All study medication canister product-identifying text graphic ( e.g. , mold text actuator ) mask treatment identify . No subject study arm give information could reveal nature treatment give . All study subject instruct reveal discus study medication study staff subject . The designated study evaluator ( ) , conduct clinical visit safety efficacy evaluation perform data record transcription , blind study medication . All subject screen enrollment , randomize follow three treatment group double-blinded ( Treatments T P ) evaluator-blinded ( Treatment R ) manner : Treatment T ( Albuterol-HFA , N=200 ) : 216 mcg albuterol sulfate ( equivalent 180 mcg albuterol base ) , QID ; Treatment R ( Proventil-HFA , N=50 ) : 216 mcg albuterol sulfate ( equivalent 180 mcg albuterol base ) , QID ; Treatment P ( Placebo-HFA , N=50 ) : two actuation placebo , QID . Randomization achieve block six ( 6 ) , four ( 4 ) patient receive Albuterol-HFA every one ( 1 ) patient receive Proventil-HFA every one ( 1 ) receive Placebo-HFA . At Clinical Visit take place every 3 week , double-blinded ( T , P ) evaluator-blinded ( R ) study drug distribute resealable masking pouch subject arm . An additional aim study evaluate effect weekly cleaning Albuterol-HFA MDI device clinical performance throughout four , 3-week life-of-device treatment cycle , conformance FDA 's specific requirement . Arms : All subject screen enrollment , randomize follow three treatment group double-blinded ( Treatments T P ) evaluator-blinded ( Treatment R ) manner : Treatment T ( Albuterol-HFA , N=200 ) : 216 mcg albuterol sulfate ( equivalent 180 mcg albuterol base ) , QID ; Treatment R ( Proventil-HFA , N=50 ) : 216 mcg albuterol sulfate ( equivalent 180 mcg albuterol base ) , QID ; Treatment P ( Placebo-HFA , N=50 ) : two actuation placebo , QID .</detailed_description>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Male female asthma patient age 12 75 year , general good health . A documented history mild moderate asthma , atleast 6months prior Screening , require inhale B2adrenergic agonist , without orally inhaled corticosteroid , asthma treatment . Satisfying criterion asthma stability , define asthmarelated hospitalization emergency visit , significant change asthma therapy , 4 week prior Screening ( exception switch long shortacting B2agonists ) . Can tolerate withholding treatment inhale bronchodilator allow medication minimum washout period indicate Appendix II prior Screening Baseline FEV1 test . Having Screening Baseline FEV1 test fall within 5090 % predict value . Airway Reversibility PFT screen demonstrate great 12 % increase FEV1 30 minute inhale 2 actuation VentolinHFA ( 180 mcg albuterol base ) . Demonstrating satisfactory technique use metereddose inhaler ( MDIs ) hand hold peak flow meter . Female patient childbearing potential nonpregnant nonlactating Screening throughout study , use acceptable method contraception study . Has properly consent participate study . Male female asthma patient age 12 75 year , general good health . A documented history mild moderate asthma , atleast 6months prior Screening , require inhale B2adrenergic agonist , without orally inhaled corticosteroid , asthma treatment . Satisfying criterion asthma stability , define asthmarelated hospitalization emergency visit , significant change asthma therapy , 4 week prior Screening ( exception switch long shortacting B2agonists ) . Can tolerate withholding treatment inhale bronchodilator allow medication minimum washout period indicate Appendix II prior Screening Baseline FEV1 test . Having Screening Baseline FEV1 test fall within 5090 % predict value . Airway Reversibility PFT screen demonstrate great than12 % increase FEV1 30 minute inhale 2 actuation VentolinHFA ( 180 mcg albuterol base ) . Demonstrating satisfactory technique use metereddose inhaler ( MDIs ) hand hold peak flow meter . Female patient childbearing potential nonpregnant nonlactating Screening throughout study , use acceptable method contraception study . Has properly consent participate study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>albuterol</keyword>
	<keyword>HFA</keyword>
</DOC>